Search results for "double-blind method"

showing 10 items of 631 documents

Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

1987

Opiates stimulate the growth hormone and prolactin responses to stimuli in non-obese humans. Obese patients, however, show lowered growth hormone and prolactin responses and raised beta-endorphin levels. We therefore investigated the effect of the opiate antagonist naloxone on the stimulated growth hormone and prolactin secretions in a controlled double-blind study in obese patients. All patients received 200 micrograms TRH and 0.5 g/kg b.w. arginine together with 2 mg of naloxone or placebo i.v. in a randomized sequence. The TRH- and arginine-induced increases in prolactin and growth hormone were significantly greater after administration of naloxone (p less than 0.05). Naloxone also produ…

AdultMaleendocrine systemmedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and Metabolismmedicine.medical_treatment(+)-NaloxoneArginineGlucagonEndocrinologyAdrenocorticotropic HormoneDouble-Blind MethodInternal medicinemedicineHumansObesityOpioid peptideThyrotropin-Releasing HormoneTriiodothyroninebusiness.industryNaloxoneInsulinbeta-EndorphinAntagonistMiddle AgedProlactinProlactinEndocrinologyGrowth HormoneFemaleEndorphinsOpiatebusinesshormones hormone substitutes and hormone antagonistsJournal of endocrinological investigation
researchProduct

Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion

2012

Background/Aim:Liraglutide, a glucagon-like peptide-1 analog, induces weight loss. We investigated whether liraglutide affects gastric accommodation and satiation by measuring the intragastric pressure (IGP) during nutrient-drink consumption and using the barostat technique.Methods:Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration. IGP was studied during intragastric nutrient-drink (1.5 kcal ml(-1)) infusion (60 ml min(-1)), while the HVs scored their satiation on a graded scale until maximal satiation. In a separate session, isobaric distentions were performed using the barostat with stepwise increments of 2 mm Hg starting from minimal di…

AdultMaleendocrine systemmedicine.medical_specialtyManometryEndocrinology Diabetes and MetabolismTreatment outcomeMedicine (miscellaneous)SatiationSettore BIO/09 - FisiologiaBody Mass IndexBeveragesEatingDouble-Blind MethodGlucagon-Like Peptide 1Internal medicinegastric accomodation GLP-1 satiationPressuremedicineHumansIngestionNutrition and DieteticsDose-Response Relationship DrugLiraglutidebusiness.industryStomachdigestive oral and skin physiologyNauseaLiraglutidePostprandial PeriodTreatment OutcomeEndocrinologyGastric EmptyingFemaleGastrointestinal Motilitybusinessmedicine.drugInternational Journal of Obesity
researchProduct

Neuroendocrine response to antipsychotics: effects of drug type and gender

1999

Abstract Background: To study the influences of drug type and gender on the neuroendocrine response to neuroleptic treatment, we compared the endocrine actions of two neuroleptics with different receptor affinity profiles—a substituted benzamide, amisulpride, a selective D 2 -like dopamine antagonist; and a thioxanthene, flupenthixol, a mixed D 1 /D 2 -like antagonist also blocking serotonin, H 1 , and D 1 receptors—on anterior pituitary hormone secretion in schizophrenic patients (DSM-III-R). Methods: Blood was withdrawn at 15-min intervals to assess basal secretion of prolactin, growth hormone (GH), and thyroid-stimulating hormone (TSH). Four hundred micrograms of thyrotropin-releasing ho…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesThyrotropinThyrotropin-releasing hormoneFlupenthixolPharmacologySex FactorsDouble-Blind MethodAnterior pituitaryThyroid-stimulating hormoneInternal medicinemedicineHumansAmisulprideBiological PsychiatryHuman Growth Hormonebusiness.industryDopamine antagonistNeurosecretory SystemsProlactinProlactinFlupenthixolmedicine.anatomical_structureEndocrinologySchizophreniaFemaleSchizophrenic PsychologyAmisulprideSulpiridebusinesshormones hormone substitutes and hormone antagonistsAntipsychotic Agentsmedicine.drugHormoneBiological Psychiatry
researchProduct

Food-additive-induced urticaria: a survey of 838 patients with recurrent chronic idiopathic urticaria

2005

<i>Background:</i> Recurrent chronic idiopathic urticaria (RCIU) is a common skin condition that affects 0.1–3% of the population in the USA and Europe and accounts for nearly 75% of all ‘ordinary’ chronic urticaria (CU) cases. <i>Methods:</i> We studied 838 consecutive patients with RCIU referred to hospital between 1998 and 2003. Patients with known causes of CU were excluded. Clinical history, physical examination, and symptom diaries were evaluated during two periods, a diet-free period (1 week) and a food-additive-free diet (FAFD) period (4 weeks), respectively, and two double-blind placebo-controlled (DBPC) challenges of six food additives were administered. Th…

AdultMalefood.ingredientSettore MED/09 - Medicina InternaAdolescentUrticariaImmunologyPopulationPlacebofoodDouble-Blind MethodRecurrenceImmunopathologyPrevalenceHumansImmunology and AllergyMedicinesurveyeducationFood-additive-induced urticariaAgededucation.field_of_studyrecurrent chronic idiopathic urticariaFood-additive-induced urticaria; survey; recurrent chronic idiopathic urticariabusiness.industryFood additiveGeneral MedicineMiddle AgedFood hypersensitivityChronic diseaseChronic DiseaseImmunologyFemaleFood AdditivesChronic idiopathic urticariabusinessFood Hypersensitivity
researchProduct

Visual Performance of Four Simultaneous-Image Multifocal Contact Lenses Under Dim and Glare Conditions

2014

To assess and compare the effects of four simultaneous-image multifocal contact lenses (SIMCLs), and those with distant-vision-only contact lenses on visual performance in early presbyopes, under dim conditions, including the effects of induced glare.In this double-masked crossover study design, 28 presbyopic subjects aged 40 to 46 years were included. All participants were fitted with the four different SIMCLs (Air Optix Aqua Multifocal [AOAM; Alcon], PureVision Multifocal [PM; BauschLomb], Acuvue Oasys for Presbyopia [AOP; JohnsonJohnson Vision], and Biofinity Multifocal [BM; CooperVision]) and with monofocal contact lenses (Air Optix Aqua, Alcon). After 1 month of daily contact lens wear…

AdultMalegenetic structuresContact LensesComputer scienceCrossoverVisual AcuityGlareContrast SensitivityOpticsDouble-Blind MethodHumansLightingAnalysis of VarianceCross-Over Studiesbusiness.industryGlare (vision)PresbyopiaMiddle AgedCrossover studyeye diseasesOphthalmologyOptometryFemalesense organsbusinessEye & Contact Lens: Science & Clinical Practice
researchProduct

Objective analysis of contact lens fit.

2015

Purpose: To assess the validity and repeatability of objective compared to subjective contact lens fit analysis. Methods: Thirty-five subjects (aged 22.0. ±. 3.0 years) wore two different soft contact lens designs. Four lens fit variables: centration, horizontal lag, post-blink movement in up-gaze and push-up recovery speed were assessed subjectively (four observers) and objectively from slit-lamp biomicroscopy captured images and video. The analysis was repeated a week later. Results: The average of the four experienced observers was compared to objective measures, but centration, movement on blink, lag and push-up recovery speed all varied significantly between them (p 0.05). The 95% conf…

AdultMalegenetic structuresObjective analysisObjective assessmentCorneaDouble-Blind MethodStatisticsMyopiaHumansMathematicsFit/gap analysisBlinkingbusiness.industryObjective measurementReproducibility of ResultsGeneral MedicineRepeatabilityEquipment DesignContact Lenses HydrophilicCentrationConfidence intervalContact lensOphthalmologyFemaleNuclear medicinebusinessOptometryContact lensanterior eye : the journal of the British Contact Lens Association
researchProduct

Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.

2018

Aims Aim of this study was to associate concentration of naltrexone and its major active metabolite 6β-naltrexol in blood with therapeutic outcome during treatment with naltrexone in subjects with alcohol dependence. Treatment with the μ-opiate receptor antagonist naltrexone has been shown to reduce craving for alcohol and alcohol intake in patients suffering from alcohol dependence. Short summary This article shows the use of therapeutic drug monitoring in alcohol dependent patients, who are treated with naltrexone. The plasma concentrations of naltrexone and 6β-naltrexol showed high inter-individual variability. They were predictive for treatment response, as they correlated significantly…

AdultMalemedicine.drug_classAcamprosateNarcotic Antagonists030508 substance abuseCravingAlcoholPharmacologyNaltrexone03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodReference ValuesmedicineHumansActive metaboliteCravingEthanolmedicine.diagnostic_testbusiness.industryAlcohol dependenceGeneral MedicineMiddle AgedReceptor antagonistNaltrexoneAlcoholismTreatment OutcomechemistryTherapeutic drug monitoringDrug Therapy CombinationFemalemedicine.symptomDrug Monitoring0305 other medical sciencebusiness030217 neurology & neurosurgerymedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

A double-blind study comparing paroxetine and maprotiline in depressed outpatients.

1997

A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comp…

AdultMalemedicine.drug_classDouble-Blind MethodAnticholinergicAmbulatory CareMedicineHumansPharmacology (medical)Adverse effectMaprotilinePsychiatric Status Rating ScalesBenzodiazepineDepressive Disorderbusiness.industryGeneral MedicineParoxetinePsychiatry and Mental healthParoxetineMaprotilineConcomitantAnesthesiaAntidepressantAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome

1998

In a multicenter, double-blind, parallel group trial, the efficacy of risperidone (RIS) was compared with a combination of haloperidol and amitriptyline (HAL/AMI) over 6 weeks in patients with coexisting psychotic and depressive symptoms with either a schizoaffective disorder, depressive type, a major depression with psychotic features, or a nonresidual schizophrenia with major depressive symptoms according to DSM-III-R criteria. A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6.9 mg RIS versus 9 mg HAL combined with 180 mg AMI. Efficacy results for those 98 patients (47 RIS; 51 HAL/AMI) who completed at least 3 weeks of double-blind treatme…

AdultMalemedicine.medical_specialtyAdolescentAmitriptylineSchizoaffective disorderAntidepressive Agents Tricycliclaw.inventionDouble-Blind MethodExtrapyramidal symptomsRandomized controlled triallawInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmitriptylinePsychiatryAgedPsychiatric Status Rating ScalesDepressive DisorderRisperidoneMiddle AgedRisperidonemedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaHaloperidolFemalemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct